

- **Investment Rational**
Edity is developing a unique technology which uses immune cells to transfer novel therapeutic proteins to target cells to enable the body to re-establish homeostasis. Such a technology could enable application of many novel classes of protein including gene editors and signaling proteins to treat patients who currently lack good options for treatment of chronic disease.
- **Business Strategy**
Edity is developing internal therapeutic programmes and will also seek to form strategic partnerships to develop therapies for additional indications. Revenue will consist of technology access fees, clinical development milestones and on market royalties from strategic partners over the short, medium and long term respectively.
- **Core Technology**
The benefit of the technology is two fold. Firstly novel proteins can be chaperoned and delivered by engineered immune cells, broadening the range of protein modalities that can be considered. Secondly precise delivery direct to the cytoplasm of target cells which in conjunction with other cell therapy approaches would enable tissue specific delivery beyond the liver and the eye.
- **Product Profile/Pipeline**
Edity is emerging from stealth mode and preparing for a Series A funding round. We expect to announce our first strategic partnership in the coming 9-12 months. We have one internal therapeutic programme that is pre-IND based on a novel signal protein. Additionally we have discovery programmes based on using gene editors in conjunction with our technology.
- **What's Next?**
In vivo proof of concept is a key focus for 2022 both for the technology platform and more specifically for our internal therapeutic programme. In parallel we are working to extend our funding and will likely pursue a Series A funding in 2022.